Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AIM ImmunoTech Inc.
< Previous
1
2
Next >
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
September 11, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
August 20, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 16, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
August 13, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
July 29, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
July 24, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
July 03, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
June 10, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
June 03, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
May 31, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
May 20, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 16, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
May 09, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
May 06, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
April 29, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 25, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
April 15, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 11, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
April 10, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
April 02, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
March 28, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
March 26, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
March 25, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 22, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 20, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Launch of CEO Corner Platform
March 07, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
February 29, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
February 14, 2024
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.